95 related articles for article (PubMed ID: 18927286)
1. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
2. Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.
Wood PM; Woo LW; Thomas MP; Mahon MF; Purohit A; Potter BV
ChemMedChem; 2011 Aug; 6(8):1423-38. PubMed ID: 21608133
[TBL] [Abstract][Full Text] [Related]
3. Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach.
Singh Y; Jaswal S; Singh S; Verma SK; Thareja S
J Biomol Struct Dyn; 2023 Dec; 41(20):10604-10626. PubMed ID: 36510679
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
[TBL] [Abstract][Full Text] [Related]
5. Aromatase and steroid sulfatase from human placenta.
Ghosh D
Methods Enzymol; 2023; 689():67-86. PubMed ID: 37802583
[TBL] [Abstract][Full Text] [Related]
6. Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.
Woo LW; Bubert C; Purohit A; Potter BV
ACS Med Chem Lett; 2011 Mar; 2(3):243-7. PubMed ID: 24900302
[TBL] [Abstract][Full Text] [Related]
7. IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Palmieri C; Szydlo R; Miller M; Barker L; Patel NH; Sasano H; Barwick T; Tam H; Hadjiminas D; Lee J; Shaaban A; Nicholas H; Coombes RC; Kenny LM
Breast Cancer Res Treat; 2017 Nov; 166(2):527-539. PubMed ID: 28795252
[TBL] [Abstract][Full Text] [Related]
8. The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors.
Secky L; Svoboda M; Klameth L; Bajna E; Hamilton G; Zeillinger R; Jäger W; Thalhammer T
J Drug Deliv; 2013; 2013():957605. PubMed ID: 23476785
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Thomas MP; Potter BV
J Med Chem; 2015 Oct; 58(19):7634-58. PubMed ID: 25992880
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.
Woo LW; Wood PM; Bubert C; Thomas MP; Purohit A; Potter BV
ChemMedChem; 2013 May; 8(5):779-99. PubMed ID: 23495205
[TBL] [Abstract][Full Text] [Related]
11. In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.
McNamara KM; Guestini F; Sauer T; Touma J; Bukholm IR; Lindstrøm JC; Sasano H; Geisler J
Br J Cancer; 2018 May; 118(9):1208-1216. PubMed ID: 29563635
[TBL] [Abstract][Full Text] [Related]
12. Brain Gene Expression in a Novel Mouse Model of Postpartum Mood Disorder.
Humby T; Davies W
Transl Neurosci; 2019; 10():168-174. PubMed ID: 31410299
[TBL] [Abstract][Full Text] [Related]
13. Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.
Read ML; Fong JC; Modasia B; Fletcher A; Imruetaicharoenchoke W; Thompson RJ; Nieto H; Reynolds JJ; Bacon A; Mallick U; Hackshaw A; Watkinson JC; Boelaert K; Turnell AS; Smith VE; McCabe CJ
Oncogene; 2017 Sep; 36(37):5296-5308. PubMed ID: 28504713
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice.
Gaspal F; Withers D; Saini M; Bekiaris V; McConnell FM; White A; Khan M; Yagita H; Walker LS; Anderson G; Lane PJ
J Exp Med; 2011 Aug; 208(8):1579-84. PubMed ID: 21788408
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade.
Daśko M; Demkowicz S; Biernacki K; Ciupak O; Kozak W; Masłyk M; Rachon J
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1163-1184. PubMed ID: 32363947
[TBL] [Abstract][Full Text] [Related]
16. SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects.
Potter BVL
J Mol Endocrinol; 2018 Aug; 61(2):T233-T252. PubMed ID: 29618488
[TBL] [Abstract][Full Text] [Related]
17. Targeting the formation of estrogens for treatment of hormone dependent diseases-current status.
Rižner TL; Romano A
Front Pharmacol; 2023; 14():1155558. PubMed ID: 37188267
[TBL] [Abstract][Full Text] [Related]
18. Pyridine based dual binding site aromatase (CYP19A1) inhibitors.
Eissa AG; Powell LE; Gee J; Foster PA; Simons C
RSC Med Chem; 2023 Feb; 14(2):356-366. PubMed ID: 36846364
[TBL] [Abstract][Full Text] [Related]
19. Steroid Sulphatase and Its Inhibitors: Past, Present, and Future.
Foster PA
Molecules; 2021 May; 26(10):. PubMed ID: 34064842
[TBL] [Abstract][Full Text] [Related]
20. New potent steroid sulphatase inhibitors based on 6-(1-phenyl-1
Ciupak O; Daśko M; Biernacki K; Rachon J; Masłyk M; Kubiński K; Martyna A; Demkowicz S
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):238-247. PubMed ID: 33322953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
